Skip to main content

What the FDA labels say about taking them together

Apomorphine and palonosetron

Apomorphine's FDA label of February 24, 2022 names palonosetron in its contraindications section; the palonosetron labels PlainMeds reads (2) do not name apomorphine. The apomorphine label: “CONTRAINDICATIONS ONAPGO is contraindicated in patients: Using concomitant 5HT 3 antagonists, including antiemetics and alosetron.”

Check it at the source: the apomorphine FDA label on DailyMed (effective February 24, 2022, TruPharma, LLC); the palonosetron FDA label on DailyMed (effective April 29, 2025, Avyxa Pharma, LLC).

What does the apomorphine label say about palonosetron?

Apomorphine label, contraindications

CONTRAINDICATIONS Apomorphine hydrocloride is contraindicated in patients: Using concomitant drugs of the 5HT 3 antagonist class including antiemetics (e.g., ondansetron, granisetron, dolasetron, palonosetron) and alosetron [see Drug Interactions (7.1) ].

Apomorphine label, drug interactions

DRUG INTERACTIONS Concomitant use of antihypertensive medications and vasodilators: increased risk for hypotension, myocardial infarction, pneumonia, falls, and injuries ( 7.2 ) Dopamine antagonists such as neuroleptics or metoclopramide, may diminish the effectiveness of apomorphine hydrocloride ( 7.4 ) 7.1 5HT 3 Antagonists Based on reports of profound hypotension and loss of consciousness when apomorphine hydrocloride was administered with ondansetron, the concomitant use of apomorphine hydrocloride with 5HT 3 antagonists including antiemetics (for example, ondansetron, granisetron, dolasetron, palonosetron) and alosetron, is contraindicated.

Source: FDA drug label (Onapgo, NDA214056), MDD US Operations, LLC, a subsidiary of Supernus Pharmaceuticals, Inc, effective July 10, 2026 (SPL set f3552b6e-5ae7-4993-aa1a-e399c4a7080a), via openFDA

Source: FDA drug label (apomorphine hydrocloride), ANDA212025 (Tp Anda Holdings), as published by TruPharma, LLC, effective February 24, 2022 (SPL set aedf70e4-1949-44bc-bf1b-0f282c4f0705), via openFDA; the full label on DailyMed

What does the palonosetron label say about apomorphine?

Palonosetron's label (effective April 29, 2025) and its 1 other brand-application label do not name apomorphine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (posfrea), Avyxa Pharma, LLC, effective April 29, 2025 (SPL set 13a201ba-c86d-48c5-a0e1-a3e0b4e6a2a7), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

1Apomorphine generic labelers
13Palonosetron generic labelers
ApomorphinePalonosetron
Labeled forParkinson's diseaseNausea and vomiting
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?